Stratified medicine in selecting biologics for the treatment of severe asthma

Current Opinion in Allergy and Clinical Immunology

Volumn 11, Issue 1, 2011, Pages 58-63

  Morjaria, Jaymin B ^a   Proiti, Maria ^b   Polosa, Riccardo ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Biologics; monoclonal antibodies; severe asthma

Indexed keywords

AMG 317; ANTIASTHMATIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; DACLIZUMAB; ETANERCEPT; GOLIMUMAB; IMMUNOGLOBULIN E; MASITINIB; MEPOLIZUMAB; OMALIZUMAB; PREDNISOLONE; TRIAMCINOLONE; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ARTICLE; DOUBLE BLIND PROCEDURE; DRUG BINDING; DRUG EFFICACY; DRUG SAFETY; HUMAN; PEAK EXPIRATORY FLOW; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIBODIES, MONOCLONAL; ASTHMA; BIOLOGICAL PRODUCTS; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, INTERLEUKIN-4; THIAZOLES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650821982     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3283423245     Document Type: Article

References (64)

1. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006; 368:780-793.
2. Chanez P, Wenzel SE, Anderson GP, et al. Severe asthma in adults: what are the important questions? J Allergy Clin Immunol 2007; 119:1337-1348.
3. Morjaria JB, Polosa R. Recommendation for optimal management of severe refractory asthma. J Asthma Allergy 2010; 3:43-56.
4. Currie GP, Douglas JG, Heaney LG. Difficult to treat asthma in adults. Br Med J 2009; 338:b494.
5. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181:315-323.
6. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol 2008; 8:218-230.
7. Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med 2001; 344:30-37.
8. Knight DA, Holgate ST. The airway epithelium: structural and functional properties in health and disease. Respirology 2003; 8:432-446.
9. Morjaria JB, Babu KS, Holgate ST, Polosa R. Tumour necrosis factor alpha as a therapeutic target in asthma. Drug Discovery Today Therapeut Strat 2006; 3:309-316.
10. Wilson SJ, Wallin A, Della-Cioppa G, et al. Effects of budesonide and formoterol on NF-kappaB, adhesion molecules, and cytokines in asthma. Am J Respir Crit Care Med 2001; 164:1047-1052.
11. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol 2008; 8:205-217.
12. Presta L, Shields R, O'Connell L, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994; 269:26368-26373.
13. Shields RL, Whether WR, Zioncheck K, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 1995; 107:308-312.
14. Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006:CD003559.
15. Ohta K, Miyamoto T, Amagasaki T, Yamamoto M. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma. Respirology 2009; 14:1156-1165.
16. Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009; 124:1210-1216.
17. Massanari M,Milgrom H, Pollard S, et al. Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate: severe allergic asthma. Clin Pediatr (Phila) 2009; 48:859-865.
18. Meno-Tetang GM, Lowe PJ. On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. Basic Clin Pharmacol Toxicol 2005; 96:182-192.
19. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2007; 63:548-561.
20. Slavin RG, Ferioli C, Tannenbaum SJ, et al. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol 2009; 123:107 e3-113 e3.
21. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309-316.
22. Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 2009; 68:61-76.
23. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-190.
24. Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant antiimmunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34:632-638.
25. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254-261.
26. Broide DH, Lotz M, Cuomo AJ, et al. Cytokines in symptomatic asthma airways. J Allergy Clin Immunol 1992; 89:958-967.
27. Cembrzynska-Nowak M, Szklarz E, Inglot AD, Teodorczyk-Injeyan JA. Elevated release of tumor necrosis factor-alpha and interferon-gamma by bronchoalveolar leukocytes from patients with bronchial asthma. Am Rev Respir Dis 1993; 147:291-295.
28. Thomas PS, Heywood G. Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax 2002; 57:774-778.
29. Tillie-Leblond I, Guery BP, Janin A, et al. Chronic bronchial allergic inflammation increases alveolar liquid clearance by TNF-alpha-dependent mechanism. Am J Physiol Lung Cell Mol Physiol 2002; 283:L1303-L1309.
30. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNF{alpha}) as a novel therapeutic target in symptomatic corticosteroid- dependent asthma. Thorax 2005; 60:1012-1018.
31. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006; 354:697-708.
32. Morjaria JB, Chauhan AJ, Babu KS, et al. The role of a soluble Tnf-A receptor fusion protein (etanercept) in corticosteroid-refractory asthma: a double blind, randomised placebo-controlled trial. Thorax 2008; 63:584-591.
33. Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179:549-558.
34. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol 2006; 24:147-174.
35. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as antiinterleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003; 167:199-204.
36. Menzies-Gow A, Robinson DS. Eosinophils, eosinophilic cytokines (interleukin-5), and antieosinophilic therapy in asthma. Curr Opin Pulm Med 2002; 8:33-38.
37. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood 1992; 79: 3101-3109.
38. Simon D, Braathen LR, Simon HU. Eosinophils and atopic dermatitis. Allergy 2004; 59:561-570.
39. Lopez AF, Sanderson CJ, Gamble JR, et al. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med 1988; 167: 219-224.
40. Clutterbuck EJ, Hirst EM, Sanderson CJ. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood 1989; 73:1504-1512.
41. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2144-2148.
42. Buttner C, Lun A, Splettstoesser T, et al. Monoclonal antiinterleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J 2003; 21:799-803.
43. Menzies-Gow A, Flood-Page P, Sehmi R, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 2003; 111:714-719.
44. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176:1062-1071.
45. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003; 112:1029-1036.
46. Phipps S, Flood-Page P, Menzies-Gow A, et al. Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergenchallenged human atopic skin. J Invest Dermatol 2004; 122:1406-1412.
47. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisonedependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-993.
48. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973-984.
49. Azzawi M, Johnston PW, Majumdar S, et al. T lymphocytes and activated eosinophils in airway mucosa in fatal asthma and cystic fibrosis. Am Rev Respir Dis 1992; 145:1477-1482.
50. Kon OM, Kay AB. Anti-T cell strategies in asthma. Inflamm Res 1999; 48:516-523.
51. Park CS, Lee SM, Chung SW, et al. Interleukin-2 and soluble interleukin-2 receptor in bronchoalveolar lavage fluid from patients with bronchial asthma. Chest 1994; 106:400-406.
52. Robinson DS, Bentley AM, Hartnell A, et al. Activated memory T helper cells in bronchoalveolar lavage fluid from patients with atopic asthma: relation to asthma symptoms, lung function, and bronchial responsiveness. Thorax 1993; 48:26-32.
53. Busse WW, Israel E, Nelson HS, et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med 2008; 178:1002-1008.
54. Krishnamoorthy N, Oriss TB, Paglia M, et al. Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma. Nat Med 2008; 14:565-573.
55. Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 2006; 533:327-340.
56. Ingram JL, Bonner JC. EGF and PDGF receptor tyrosine kinases as therapeutic targets for chronic lung diseases. Curr Mol Med 2006; 6:409-421.
57. Chung KF, Hew M, Score J, et al. Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity. Eur Respir J 2006; 27:230-232.
58. Hahn KA, Ogilvie G, Rusk T, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008; 22:1301-1309.
59. Humbert M, de Blay F, Garcia G, et al. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroiddependent asthmatics. Allergy 2009; 64:1194-1201.
60. Webb DC, McKenzie AN, Koskinen AM, et al. Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol 2000; 165:108-113.
61. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science 1998; 282:2258-2261.
62. Grunig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998; 282:2261-2263.
63. Rolling C, Treton D, Pellegrini S, et al. IL4 and IL13 receptors share the gamma c chain and activate STAT6, STAT3 and STAT5 proteins in normal human B cells. FEBS Lett 1996; 393:53-56.
64. Corren J, Busse W, Meltzer EO, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010; 181:788-796.